Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Byondis masked antibody-drug conjugate
- Development stage
- Preclinical
- Lead developer
- Byondis
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Byondis (formerly Synthon Biopharmaceuticals) is developing a platform for masked, conditionally activated antibodies and antibody-drug conjugates (ADCs) for the treatment of various cancers. These therapeutics are designed to remain inactive in systemic circulation and become selectively activated within the tumor microenvironment, typically through cleavage by tumor-specific proteases or other local biochemical triggers. This approach aims to enhance the therapeutic index by reducing off-target toxicity while maintaining potent anti-tumor activity. The specific targets and lead candidates within this preclinical program remain undisclosed.
- Other names
- Synthon Biopharmaceuticals-undisclosed-antibody-ADC-oncology
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on Byondis masked antibody-drug conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Byondis masked antibody-drug conjugate.